A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation

Journal of Managed Care Pharmacy

Volumn 19, Issue 9, 2013, Pages 755-764

  Nellesen, Dave ^a   Yee, Kimberly ^a   Chawla, Anita ^a   Lewis, Barbara Edelman ^b,c   Carson, Robyn T ^d  

^a ANALYSIS GROUP   (United States)

^b Ironwood Pharmaceuticals Inc ^*  (Chile)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NON PRESCRIPTION DRUG;

ARTICLE; CHRONIC DISEASE; CONSTIPATION; CONSULTATION; COST OF ILLNESS; CROHN DISEASE; DRUG COST; EMERGENCY WARD; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL QUALITY OF LIFE INDEX; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HELP SEEKING BEHAVIOR; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; ICD-9-CM; IRRITABLE COLON; LABORATORY TEST; MEDICAL FEE; OUTPATIENT; OUTPATIENT CARE; PRESCRIPTION; PROFESSIONAL PRACTICE; QUALITY OF LIFE; SHORT FORM 36; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

CHRONIC DISEASE; CONSTIPATION; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 84888417273     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.9.755     Document Type: Article

References (52)

1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130(5):1377-90.
2. American Gastroenterological Association. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology. 2002;123(6):2105-07.
3. Locke GR 3rd, Pemberton JH, Phillips SF. American Gastroenterological Association medical position statement: guidelines on constipation. Gastroenterology. 2000;119(6):1761-66.
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
5. Hungin A, Chang L, Locke G, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21(11):1365-75.
6. Mayer E, NaliboffB, Lee O, Munakata J, Chang L. Review article: gender related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther. 1999;13(Suppl 2):S65-S69.
7. Whitehead W, Palsson O, Jones K. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122(4):1140-56.
8. Harris L, Hansel S, DiBaise J, Crowell MD. Irritable bowel syndrome and chronic constipation: emerging drugs, devices, and surgical treatments. Curr Gastroenterol Rep. 2006;8(4):282-90.
9. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S5-S21.
10. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599-608.
11. Choung R, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Cumulative incidence of chronic constipation: a population-based study 1988-2003. Aliment Pharmacol Ther. 2007;26(11-12):1521-28.
12. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol. 2005;100(5):1174-84.
13. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002;16(6):1171-85.
14. Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther. 2003;18(7):671-82.
15. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm. 2004;10(4):299-309. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=7003.
16. Ahn J, Brook R, Nichol B, et al. Similarities between constipation with and without irritable bowel syndrome in a California Medicaid (Medi-Cal) population: costs trends by category in the 12 months after diagnosis from 1997-2002. Gastroenterology. 2008;134(4):A-468.
17. Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a U.S. employer perspective. Arch Intern Med. 2003;163(8):929-35.
18. Damon H, Dumas P, Mion F. Impact of anal incontinence and chronic constipation on quality of life. Gastroenterol Clin Biol. 2004;28(1):16-20.
19. Slim K, Bousquet J, Kwiatkowski F, et al. Premiere validation de la version fracaise de l'index de qualite de vie pour les maladies digestives (GIQLI) [First validation of the French version of the Gastrointestinal Quality of Life Index (GIQLI)]. Gastroenterol Clin Biol. 1999;23(1):25-31.
20. Ricci J, Jhingran P, McLaughlin T, Carter EG. Costs of care for irritable bowel syndrome in managed care. J Clin Outcomes Manag. 2000;7(6):23-28.
21. Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther. 2007;26(2):237-48.
22. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11(1 Suppl):S17-S26.
23. Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002;20(7):455-62.
24. Levy RL, Von KorffM, Whitehead WE, et al. Costs of care for irritable bowel syndrome in patients in a health maintenance organization. Am J Gastroenterol. 2001;96(11):3122-29.
25. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol. 2003;98(3):600-07.
26. Martin BC, Ganguly R, Pannicker S, Frech F, Barghout V. Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome. Curr Med Res Opin. 2003;19(8):771-80.
27. Nguyen T, Palsson O, Von KorffM, et al. Health care costs and utilization in patients with chronic constipation. Gastroenterology. 2008;134 (4 Suppl 1):A280.
28. Patel RP, Petitta A, Fogel R, Peterson E, Zarowitz BJ. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol. 2002;35(1):14-20.
29. El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 2003;3(Suppl 2):S3-S11.
30. Johansson PA, Farup PG, Bracco A, Vandvik PO. How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice. BMC Gastroenterol. 2010;10:31.
31. Pekmezaris R, Aversa L, Wolf-Klein G, Cedarbaum J, Reid-Durant M. The cost of chronic constipation. J Am Med Dir Assoc. 2002;3(4):224-28.
32. Brun-Strang C, Dapoigny M, Lafuma A, Wainsten JP, Fagnani F. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. Eur J Gastroenterol Hepatol. 2007;19(12):1097-103.
33. Park JM, Choi MG, Kim YS, et al. Quality of life of patients with irritable bowel syndrome in Korea. Qual Life Res. 2009;18(4):435-46.
34. Faresjö A, Grodzinsky E, Johansson S, Wallander MA, Timpka T, Akerlind I. A population-based case-control study of work and psychosocial problems in patients with irritable bowel syndrome-women are more seriously affected than men. Am J Gastroenterol. 2007;102(2):371-79.
35. Ten Berg MJ, Goettsch WG, van den Boom G, Smout AJ, Herings RM. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. Eur J Gastroenterol Hepatol. 2006;18(5):475-81.
36. Müller-Lissner SA, Pirk O. Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol. 2002;14(12):1325-29.
37. Bentkover JD, Field C, Greene EM, Plourde V, Casciano JP. The economic burden of irritable bowel syndrome in Canada. Can J Gastroenterol. 1999;13(Suppl A):S89-S96.
38. Graham DP, Savas L, White D, et al. Irritable bowel syndrome symptoms and health-related quality of life in female veterans. Aliment Pharmacol Ther. 2010;31(2):261-73.
39. Thijssen AY, Jonkers DM, Leue C, et al. Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. J Clin Gastroenterol. 2010;44(10):e236-e241.
40. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-50.
41. Jeong JJ, Choi MG, Cho YS, et al. Chronic gastrointestinal symptoms and quality of life in the Korean population. World J Gastroenterol. 2008;14(41):6388-94.
42. Lee V, Guthrie E, Robinson A, et al. Functional bowel disorders in primary care: factors associated with health-related quality of life and doctor consultation. J Psychosom Res. 2008;64(2):129-38.
43. Amouretti M, Le PC, Gaudin AF, et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterol Clin Biol. 2006;30(2):241-46.
44. Pare P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28(10):1726-35.
45. Coffin B, Dapoigny M, Cloarec D, Comet D, Dyard F. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2004;28(1):11-15.
46. Le Pen C, Ruszniewski P, Gaudin AF, et al. The burden cost of French patients suffering from irritable bowel syndrome. Scand J Gastroenterol. 2004;39(4):336-43.
47. Si JM, Wang LJ, Chen SJ, Sun LM, Dai N. Irritable bowel syndrome consulters in Zhejiang province: the symptoms pattern, predominant bowel habit subgroups and quality of life. World J Gastroenterol. 2004;10(7):1059-64.
48. Pace F, Molteni P, Bollani S, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol. 2003;38(10):1031-38.
49. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500-11.
50. Creed F, Ratcliffe J, Fernandez L, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med. 2001;134(9 Pt 2):860-68.
51. Lee OY, Mayer EA, Schmulson M, Chang L, NaliboffB. Gender-related differences in IBS symptoms. Am J Gastroenterol. 2001;96(7):2184-93.
52. Gralnek IM, Hays RD, Kilbourne A, NaliboffB, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119(3):654-60.